Ascendis Pharma's decision to end its partnership with Novo Nordisk sent its shares lower, but analysts at Wedbush argue the selloff misses the bigger picture. The company said it will terminate the collaboration, which means several metabolic and cardiovascular programs, including the highly anticipated once-monthly obesity drug TransCon Semaglutide, will revert to Ascendis' control.
What happened
Ascendis announced it is ending its 2024 partnership with Novo Nordisk, a deal that had been seen as a major validation of Ascendis' technology platform. Under the original agreement, Novo Nordisk had licensed rights to develop and commercialize certain metabolic and cardiovascular candidates, including TransCon Semaglutide, a once-monthly formulation of the same active ingredient in Novo Nordisk's blockbuster weight-loss drug Wegovy.
With the termination, all rights to these programs will return to Ascendis. The company said it plans to push ahead with development on its own, rather than seeking another partner immediately.
The news initially weighed on Ascendis' stock, as investors appeared to interpret the split as a setback. But Wedbush, an investment bank, pushed back on that reading, arguing that the market reaction missed what actually changed.
Why the selloff may be overdone
Wedbush analysts said investors seemed to view the end of the Novo Nordisk deal as a loss of capability or credibility. But they believe Ascendis is well-positioned to run the program solo, pointing to the company's track record in metabolic disorders. Ascendis has already brought products to market using its TransCon technology, which is designed to allow for less frequent dosing of certain drugs.
The key asset in question is TransCon Semaglutide, a once-monthly version of semaglutide, the active ingredient in Novo Nordisk's wildly popular obesity and diabetes treatments. If successful, a once-monthly injection could offer a significant convenience advantage over the weekly injections currently on the market, potentially appealing to patients who struggle with frequent dosing.
Wedbush's view is that Ascendis has the expertise and infrastructure to advance the program without a big pharma partner. The firm also noted that the company has three prior metabolic-disorder programs that have progressed through development, suggesting it knows how to navigate the regulatory and clinical hurdles.
What it means for investors
For everyday investors, the key takeaway is that the end of a partnership is not automatically bad news. In this case, Ascendis gets back full control of a promising asset, which could mean a larger share of any future profits if the drug succeeds. However, it also means the company bears the full cost and risk of development, which is why the market may have initially reacted negatively.
The obesity drug market is one of the most closely watched areas in biotech, with demand for weight-loss treatments soaring. A once-monthly option could be a differentiator, but it also faces stiff competition from established players like Novo Nordisk and Eli Lilly, which already have weekly products on the market and are developing their own longer-acting versions.
Ascendis will need to demonstrate that it can fund and execute the clinical trials required to bring TransCon Semaglutide to market. That could mean raising capital or eventually seeking a new partner, though the company has not indicated any immediate plans to do so.
For now, the market's reaction suggests uncertainty about Ascendis' ability to go it alone. But Wedbush's counterargument highlights that the company has been here before, and that the loss of a partner does not necessarily diminish the underlying value of the drug candidate.
Looking ahead
Investors will be watching for more details on Ascendis' development plans for TransCon Semaglutide, including the timeline for clinical trials and any updates on its other metabolic programs. The company's ability to manage its cash burn while advancing multiple programs will also be a focus.
The broader context is that the obesity drug space remains red-hot, with new entrants and new formulations constantly emerging. Ascendis' once-monthly approach could carve out a niche, but it will need to prove its efficacy and safety in head-to-head comparisons with existing treatments.
In the meantime, the Wedbush note serves as a reminder that market reactions to corporate news are not always rational. For investors, the lesson is to look beyond the immediate stock move and consider the underlying fundamentals.
